4D Molecular Therapeutics, Inc. (FDMT) Net income 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$140.1MFY2025 · since FY2019: -$49.3M → -$140.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$140.1M | +12.9% |
| FY2024 | -$160.9M | -59.5% |
| FY2023 | -$100.8M | +6.2% |
| FY2022 | -$107.5M | -50.7% |
| FY2021 | -$71.3M | -25.8% |
| FY2020 | -$56.7M | -15.0% |
| FY2019 | -$49.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating marginFDMT Operating cash flowFDMT Free cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →